Pfizer Inc. (NYSE:PFE) surprised investors by reporting it is ending advancement of an experimental cholesterol-lowering medication that was expected to be a blockbuster, and posted third-quarter earnings that came short of analysts’ projections.
Bococizumab reported to have unexpected side effects and moreover, it was turning out to be less effective over time. Stopping two final-stage phases of the treatment will have negative impact on full-year adjusted earnings. Two similar medications are already sold by peers, and sales of Pfizer’s were estimated to touch $958 million by 2022. Market experts said that this news came unexpected, and was unusual considering the late-stage advancement of the product. This step further narrows company’s already-thin pipeline.
The profit in 3Q2016 came at 61 cents a share, short of the estimate of 62 cents a share. CEO Ian Read stated that the firm decided to stop development of bococizumab after evaluating the competitive landscape and closing it wouldn’t meaningfully benefit patients or achieve commercial success. Read said the firm recently received results that proved a “substantial” lessening of the medicine’s impact on subjects’ LDL cholesterol at 1 year. Also, immune system responses were noted in subjects on the medication, and reactions at the point of injection.
For the first time, the company has missed profit estimates since 1Q2013, and the distress comes after numerous attempts by Pfizer to implement major strategic changes. A couple of months ago, the company decided not to split into 2 firms, ending 4 years of speculation of a probable breakup, and to keep older medicines and new products that have lost patent. Pfizer, which moved away from a $160 billion deal in April due to regulatory hurdles, is using contracts to add promising medications.
In 3Q2016, the revenue surged 7.9% to $13.1 billion, and successfully met the analysts’ estimates. Pain medicine of Lyrica revenue jumped 2% $1.24 billion, compared to projections of $1.23 billion. For FY2016, Pfizer expects adjusted EPS to come in between $2.42 per share and $2.47 a share, excluding expenses of 4 cents for the suspension of the bococizumab development plan.
DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of journaltranscript.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to:
The Next Big Thing In Biotech?https://journaltranscript.com
Get our top rated alerts on the biotech sector
Miner Stock About To Explodehttps://www.journaltranscript.com
Investors are flocking to this stock like no tomorrow !
Traders Need To Know This Nowhttps://journaltranscript.com
WallStreet is loading up on this stock. Find out why